Jump to navigation
DiaSorin Group
DiaSorin Immunodiagnostic
DiaSorin Molecular
Luminex
GROUP WEBSITES
Group
Sustainability
Governance
Investors
Media
People
Italiano
English
Home
/
Investors
/
Financial corner
/
Press releases
/
DiaSorin commercializes molecular reagent for monkeypox virus
DiaSorin commercializes molecular reagent for monkeypox virus
Mon, 11/07/2022 - 07:12
pdf
Download file
149KB
Group
About Us
Knowledge is key
Our history
Our People
Business Model
Sustainability
Our commitment
NFD 2022
Sustainability projects
Fondazione DiaSorin
Reports and non-financial statements
Governance
Mandatory Financial Disclosures
Governance documents
By-Laws
Procedures
Code of Ethics and Model 231
Reports on Corporate Governance
Corporate bodies
Shareholder's Meeting
Remuneration
Reports on remuneration
Information Documents Incentive Plans
Internal Dealing operations
Buy back program
Ownership structure
Total shareholders' basis
Loyalty shares
Investors
Investor Day 2021
Business development
Projects
Luminex acquisition
COVID-19 | Updates
Stock price
Financial corner
Results
Press releases
Presentations
Annual & Interim Reports
2022 Report
Bond
Consolidated data
Interactive KPI
Coverage
Information documents
Calendar
Keep in touch
Stock market indices and trading codes
Media
Press releases
Image Gallery
Top Management
Research laboratory
Corporate
Video gallery
Group
Events
People
Social Wall
Press kit
People
Meet our People
People Strategy
Talents4LIFE
Work with us